From DCAT Value Chain Insights (VCI)
Ligand Pharmaceuticals has named Matthew W. Foehr as president and chief operating officer. Previously Mr. Foehr served as the company’s executive vice president and chief operating officer. John Higgins, who had been serving as president and chief executive officer (CEO), will continue to serve as the company's CEO.
Mr. Foehr has more than 20 years of experience in the pharmaceutical industry, having managed global operations and various research and development programs. Prior to joining Ligand in 2011, he was vice president and head of consumer dermatology R&D, as well as acting chief scientific officer of dermatology, in the Stiefel division of GlaxoSmithKline (GSK). GSK acquired Stiefel in 2009 for $3.6 billion. At Stiefel Laboratories, Inc., Mr. Foehr served as senior vice president of global R&D operations, senior vice president of product development and support, and vice president of global supply chain technical services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation, including senior vice president of technical operations and vice president of manufacturing.
Source: Ligand Pharmaceuticals
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription